Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15673553 | 0.87 | HTR2B (0.46) | KCNH2HTR2BDRD2DRD4DRD3 | |
| SCHEMBL3777490 | 0.78 | KCNH2 (0.58) | KCNH2PRKCAPTPN2HTR7DRD2 | |
| SCHEMBL30153039 | 0.78 | KCNH2 (0.71) | KCNH2PRKCAPTPN2HTR7PARP1 | |
| SCHEMBL3435868 | 0.76 | KCNH2 (0.73) | KCNH2PRKCAPTPN2HTR7DRD2 | |
| SCHEMBL1769593 | 0.75 | KCNH2 (0.70) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL1769576 | 0.72 | KCNH2 (0.62) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL6369605 | 0.70 | KCNH2 (0.56) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL3783072 | 0.70 | PRKCA (0.53) | KCNH2PRKCAPTPN2HTR7HTR2B | |
| SCHEMBL3783069 | 0.70 | PRKCA (0.53) | KCNH2PRKCAPTPN2HTR7HTR2B | |
| SCHEMBL8027494 | 0.70 | KCNH2 (0.81) | KCNH2PRKCAPTPN2HTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252151-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | claimed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | claimed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | claimed |
| EP-2252151-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2252151-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2252151-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009102574-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102574-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | KCNH2 487/4885PRKCA 1788/4885PTPN2 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.